What is the maximum dose of baclofen (Lioresal) that can be administered to a patient for the treatment of chronic spasticity?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 21, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Research

The maximum recommended dose of baclofen for chronic spasticity is typically 80 mg per day, divided into 3-4 doses, as supported by the most recent and highest quality study 1. However, in some cases, doses up to 120 mg daily may be used under close medical supervision. Treatment should begin with a low dose of 5 mg three times daily, gradually increasing by 5 mg per dose every 3 days until the optimal effect is achieved. Most patients respond to doses between 40-80 mg daily. Higher doses may provide additional benefit for some patients with severe spasticity but also increase the risk of side effects such as drowsiness, dizziness, weakness, and confusion. Abrupt discontinuation of baclofen should be avoided as it can cause withdrawal symptoms including hallucinations, seizures, and rebound spasticity. For patients who don't respond adequately to oral baclofen or experience intolerable side effects, intrathecal baclofen therapy via an implanted pump may be considered, which uses much lower doses delivered directly to the spinal cord, as discussed in 2 and 1. Regular monitoring for efficacy and side effects is essential throughout treatment, with consideration of the benefits and risks of oral and intrathecal baclofen, as outlined in 3.

Some key points to consider when prescribing baclofen include:

  • Starting with a low dose and gradually increasing as needed and tolerated
  • Monitoring for side effects, particularly at higher doses
  • Avoiding abrupt discontinuation
  • Considering intrathecal baclofen for patients who do not respond to or cannot tolerate oral baclofen
  • Regularly reviewing the patient's response to treatment and adjusting the dose as needed, as suggested by 4 and 5.

Overall, the use of baclofen for chronic spasticity should be individualized, with careful consideration of the potential benefits and risks, and regular monitoring to ensure optimal treatment outcomes, as emphasized in 1.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.